Post sponsored by

MIL OSI Translation. Region: Russian Federation –

M. Mishin. Press Service of the Mayor and the Moscow Government

In January, it is planned to establish industrial-scale production of the vaccine.

As part of a post-registration study, about six thousand people were vaccinated against coronavirus vaccines. About it Sergei Sobyanin reported on the air of the TV channel “Russia 24”. In addition, about 600 health workers are vaccinated daily.

“As part of additional research, about six thousand people have already been vaccinated with vaccines, everyone is doing well. In fact, these trials do not hinder the development of industrial standards and the production of a mass vaccine. This is additional research that would make it possible to expand the circle of vaccinations, which would include elderly people and children. But nothing is stopping the industry from producing vaccines, ”the Moscow Mayor explained.

Nevertheless, according to Sergei Sobyanin, this is an extremely difficult process. It takes months to start mass production of a vaccine. The pharmaceutical companies that manufacture it operate around the clock.

“I hope that in November – December we will have the first large batches of vaccine, and in late December – early January, it is possible that the industrial scale, estimated in the millions, will already be established. And this, of course, will be the solution to the question related to the pandemic. In addition to vaccination, we have no other methods to stop the pandemic. Because endlessly living in restrictions – sanitary restrictions, self-isolation, with a ban on the work of the service sector – is impossible all the time. Therefore, the sooner the vaccine is produced, the sooner the population is vaccinated, the sooner we will end this infection, ”said Sergei Sobyanin.

Some participants in the post-marketing clinical trial of the COVID-19 vaccine have already begun to receive the second component of the Sputnik V drug. The components differ in active substances. A post-marketing clinical trial of a coronavirus vaccine began in Moscow on September 7. It is carried out on the basis of 19 medical institutions in the capital. The study will help to obtain permanent marketing authorization and expand the circle of possible vaccine recipients, including to cover the age group over 60 years. It will last 180 days. From the moment of vaccination, doctors of the telemedicine center will monitor the health of the participants for six months.

How the health of participants in a coronavirus vaccine study is monitoredCOVID-19 Vaccine Study Participants Introduced Second Component

The candidate for participation in the study must be at least 18 years old, he must not show signs of acute respiratory diseases. It is also important that there is no contact with coronavirus patients at least two weeks before the study. Participants in the study can be not only Muscovites, but also residents of other regions of Russia. Also, foreign citizens can get vaccinated.

The vaccine has already successfully passed two stages of clinical trials and has been shown to be safe. It does not contain the coronavirus itself, which means that it is impossible to get sick with it or infect others. Those who received the drug develop immunity due to the appearance of antibodies. The vaccine is tolerated by the body in the same way as a regular vaccine.

You can apply to participate in a clinical trial of a COVID-19 vaccine at

EDITOR’S NOTE: This article is a translation. Apologies should the grammar and or sentence structure not be perfect.

MIL OSI Russia News